India, April 30 -- Novocure (NVCR), an oncology company, reported financial results for the first quarter ended March 31, 2026, reflecting 12% revenue growth and lifted revenue guidance for the full year 2026.
Following the news, NVCR is up 22.73% at $14.63.
Company Profile
Novocure develops and commercialises a cancer treatment platform called Tumour Treating Fields (TTFields), a non-invasive therapy that uses electric fields to disrupt cancer cell division.
Novocure's commercialised products are approved in certain countries for the treatment of adult patients with glioblastoma, pancreatic cancer, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma.
First Quarter Results and Revised 2026 Guidance
Net ...